UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

<u>UROGEN PHARMA LTD.</u>

(Name of Issuer)

Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities)

M96088105 (CUSIP Number)

September 30, 2024 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ R:	ule 13d-1(b)					
⊠ R	ule 13d-1(c)					
□ R:	ule 13d-1(d)					
The remaind	ler of this cover page shall be	filled out for a reporting n	erson's initial filing on t	his form with respect to	the subject class of sec	purities and fo

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

	ı			
1	NAMES OF REPORTING PERSONS			
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)			
	RA Capital Management, L.P.			
	_			
2	CHECK THE A	APPRO	OPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
			$\begin{array}{ccc} \text{(a)} & \square \\ \text{(b)} & \square \end{array}$	
			(b) □	
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	Delaware			
		5	SOLE VOTING POWER	
N	UMBER OF			
	SHARES	6	SHARED VOTING POWER	
	NEFICIALLY			
	OWNED BY EACH		3,206,271	
R	EACH REPORTING	7	SOLE DISPOSITIVE POWER	
1	PERSON			
	WITH:			
		8	SHARED DISPOSITIVE POWER	
			3,206,271	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
_	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REFORMING LERSON			
	3,206,271			
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) □			
11	1 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9			
	TERCENT OF CEROS REFREDENTED BY THROUNT IN ROW 7			
	7.1%			
12	2 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)			
	IA, PN			
l				

1	NAMES OF REPORTING PERSONS			
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)			
	D . T. 11: 1			
	Peter Kolchinsk	-		
2	CHECK THE A	APPRO	OPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
			(a) \Box	
	(b) □			
3	SEC USE ONL	Y		
4	CITIZENSHIP	OR P	LACE OF ORGANIZATION	
	CITIZENDINI OKTERCE OF OKOMINEMION			
	United States of America			
		5	SOLE VOTING POWER	
			SOLE VOINGTOWER	
N	UMBER OF			
	SHARES	6	SHARED VOTING POWER	
	NEFICIALLY		SIMILE VOINVOIOWER	
	OWNED BY		3,206,271	
	EACH EPORTING	7	SOLE DISPOSITIVE POWER	
I N	PERSON	,	SOLE DISTOSTITVE TO WER	
	WITH:			
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	8	SHARED DISPOSITIVE POWER	
		0	SHARED DISTOSITIVE TOWER	
			3,206,271	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
,	AGUKEGATE AMOUNT BENEFICIALLY OWNED BY EACH KEPOKTING PEKSON			
	3,206,271			
10				
10	U CHECK DOA IF THE AGGREGATE AMOUNT IN KOW (9) EACLODES CERTAIN SHARES (SEE INSTRUCTIONS) □			
11	1 DEDCENT OF CLASS DEDDESENTED DV AMOUNT IN DOW 0			
11	1 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9			
	7.1%			
10				
12	2 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)			
	IN, HC			
	,			

1	NAMES OF REPORTING PERSONS				
-	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	INC. IDENTIFICATION TO THE OVER PERSONS (EXTITLES ONE)				
	Rajeev Shah				
2	CHECK THE A	APPRO	OPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)		
			(a) \Box		
			(b) □		
3	SEC USE ONL	Y			
4	CITIZENSHIP OR PLACE OF ORGANIZATION				
	United States of America				
		5	SOLE VOTING POWER		
N	UMBER OF SHARES		0		
BE	NEFICIALLY	6	SHARED VOTING POWER		
	OWNED BY		2 207 271		
	EACH		3,206,271		
REPORTING		7	SOLE DISPOSITIVE POWER		
PERSON					
WITH:					
		8	SHARED DISPOSITIVE POWER		
			3,206,271		
9	ACCRECATE	AMO			
,	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	3,206,271				
10	0 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) □				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				
	7.1%				
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)				
	IN, HC				
	IIV, IIC				

1	NAMES OF REPORTING PERSONS			
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)			
	RA Capital Hea	althcar	e Fund, L.P.	
2	CHECK THE A	APPRO	OPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
			(a) \Box	
			(b) □	
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	Delaware			
		5	SOLE VOTING POWER	
N	UMBER OF			
	SHARES	6	SHARED VOTING POWER	
	NEFICIALLY		STRIED FORMOTOWER	
	OWNED BY		3,206,271	
р	EACH REPORTING		SOLE DISPOSITIVE POWER	
I	PERSON	7	SOLE DISTOSTITY ETOWER	
	WITH:			
		8	SHARED DISPOSITIVE POWER	
		0	SIMILD DISTOSITIVE TO WER	
			3,206,271	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	AUGREGATE AMOUNT DENEFICIALLY OWNED DY EACH REPORTING PERSON			
	3,206,271			
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) □			
11	1 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9			
	7.1%			
12	2 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)			
	PN			
l	l			

Item 1(a). Name of Issuer:

Urogen Pharma Ltd. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

400 Alexander Park Drive, 4th Floor, Princeton, NJ 08540

Item 2(a). Names of Persons Filing:

The names of the persons filing this report (collectively, the "Reporting Persons") are:

RA Capital Management, L.P. ("RA Capital")

Peter Kolchinsky

Rajeev Shah

RA Capital Healthcare Fund, L.P. (the "Fund")

Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is: c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

Item 2(c). <u>Citizenship</u>:

RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

Item 2(d). <u>Title of Class of Securities</u>:

Ordinary Shares, par value NIS 0.01 per share

Item 2(e). CUSIP Number:

M96088105

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership.

The Fund directly holds 3,206,271 pre-funded warrants ("<u>Pre-Funded Warrants</u>") through which it has the right to acquire 3,206,271 Ordinary Shares, subject to a Beneficial Ownership Blocker (as defined below).

The shares reported herein for the Reporting Persons represent 3,206,271 Ordinary Shares that the Reporting Persons beneficially own based on the right to acquire, upon the exercise of the Pre-Funded Warrants. The Pre-Funded Warrants may be exercised for Ordinary Shares at the election of the holder, except that the agreement governing the terms of the exercise of the Pre-Funded Warrants contains a provision (the "Beneficial Ownership Blocker") which precludes the exercise of the Pre-Funded Warrants to the extent that, following the exercise, the holder, together with its affiliates and any other person acting together with the holder as a "group" (as defined in the rules under the Securities Exchange Act of 1934 (the "Act")), would beneficially own more than 9.99% of the Ordinary Shares outstanding.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G/A. The beneficial ownership percentages reported are based on the equivalent of 42,114,070 outstanding Ordinary Shares, as reported in the Issuer's Form 10-Q filed on August 13, 2024, plus (ii) 3,206,271 Ordinary Shares of which the Reporting Persons may currently acquire beneficial ownership upon the exercise of the Pre-Funded Warrants, as limited by the Beneficial Ownership Blocker.

RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's portfolio, including the Issuer's Ordinary Shares reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital, RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. <u>Identification and Classification of Members of the Group.</u>

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. <u>Certification</u>.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Exhibit List

Exhibit 1: Joint Filing Agreement

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: November 14, 2024

RA CAPITAL MANAGEMENT, L.P.

By: /s/ Peter Kolchinsky

Name: Peter Kolchinsky
Title: Authorized Signatory

PETER KOLCHINSKY

/s/ Peter Kolchinsky

RAJEEV SHAH

/s/ Rajeev Shah

RA CAPITAL HEALTHCARE FUND, L.P.

By: RA Capital Healthcare Fund GP, LLC

Its: General Partner

By: /s/ Peter Kolchinsky

Name: Peter Kolchinsky Title: Manager

AGREEMENT

This Joint Filing Agreement, dated as of November 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the "Filers").

Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Ordinary Shares, par value NIS 0.01 per share of Urogen Pharma Ltd. beneficially owned by them from time to time.

Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Filers upon one week's prior written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.

RA CAPITAL MANAGEMENT, L.P.

By: /s/ Peter Kolchinsky

Name: Peter Kolchinsky
Title: Authorized Signatory

PETER KOLCHINSKY

/s/ Peter Kolchinsky

RAJEEV SHAH

/s/ Rajeev Shah

RA CAPITAL HEALTHCARE FUND, L.P.

By: RA Capital Healthcare Fund GP, LLC

Its: General Partner

By: /s/ Peter Kolchinsky

Name: Peter Kolchinsky Title: Manager